The global spine biologics market is expected to hit $1.74 billion by 2020, according to a Technavio report.
Here are five key points:
1. The growing popularity of minimally invasive spine surgery is increasing demand for spine biologics.
2. Robot-assisted surgeries will also likely spur market growth.
3. In 2015, allografts accounted for $163.7 million within the global spine biologics market. An increase in the number of spine surgeries and rise in spine disorder cases will drive the allograft market.
Zimmer Biomet and NuVasive are both creating new products with AlloSource, an organization offering more than 200 types of bone skin, soft tissue and customized allografts.
4. In 2015, stem cells accounted for $161.1 million within the global spine biologics market. Genetic engineering advancements have allowed stem cell modification to "induce the genetic expression of growth factors that enhance tissue reconstruction."
Stem cells have aided biological reconstruction of discs for patients with degenerative spinal disorders. Additionally, mesenchymal stem cells and adipose-derived stem cells have helped with spinal fusion.
5. In 2015, the bone morphogenetic proteins market captured a 20.51 percent share of the global spine biologics market. BMP-2 and BMP-7 help with bone healing during bone fusion therapy.
About 20 BMPs are available today, but only BMP-2, BMP-4, BMP-6, BMP-7 and MBP-9 have demonstrated proof for supporting bone formation.